866-997-4948(US-Canada Toll Free)

Alzheimers Disease - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : Apr 2019

Category :

Pharmaceutical

No. of Pages : 1429 Pages

Alzheimer's Disease - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 25, 56, 60, 5, 295, 109 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 97 and 43 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents
Introduction
Alzheimer's Disease - Overview
Alzheimer's Disease - Therapeutics Development
Alzheimer's Disease - Therapeutics Assessment
Alzheimer's Disease - Companies Involved in Therapeutics Development
Alzheimer's Disease - Drug Profiles
Alzheimer's Disease - Dormant Projects
Alzheimer's Disease - Discontinued Products
Alzheimer's Disease - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Alzheimer's Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Alzheimer's Disease - Pipeline by 2A Pharma AB, H1 2019
Alzheimer's Disease - Pipeline by 4D Pharma Plc, H1 2019
Alzheimer's Disease - Pipeline by AB Science SA, H1 2019
Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2019
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2019
Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2019
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2019
Alzheimer's Disease - Pipeline by Affichem SA, H1 2019
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2019
Alzheimer's Disease - Pipeline by Alector Inc, H1 2019
Alzheimer's Disease - Pipeline by AlfaSigma SpA, H1 2019
Alzheimer's Disease - Pipeline by Allergan Plc, H1 2019
Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by ALSP Inc, H1 2019
Alzheimer's Disease - Pipeline by AlzeCure Pharma AB, H1 2019
Alzheimer's Disease - Pipeline by Alzheon Inc, H1 2019
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2019
Alzheimer's Disease - Pipeline by Alzinova AB, H1 2019
Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2019
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2019
Alzheimer's Disease - Pipeline by Amgen Inc, H1 2019
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2019
Alzheimer's Disease - Pipeline by Aphios Corp, H1 2019
Alzheimer's Disease - Pipeline by Apodemus AB, H1 2019
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2019
Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2019
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2019
Alzheimer's Disease - Pipeline by Artery Therapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by Arvinas Inc, H1 2019
Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2019
Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2019
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2019
Alzheimer's Disease - Pipeline by Auritec Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Avanir Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2019
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2019
Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H1 2019
Alzheimer's Disease - Pipeline by Axxam SpA, H1 2019
Alzheimer's Disease - Pipeline by AZTherapies Inc, H1 2019
Alzheimer's Disease - Pipeline by BCWorld Pharm Co Ltd, H1 2019
Alzheimer's Disease - Pipeline by Beactica AB, H1 2019

List of Figures
Number of Products under Development for Alzheimer's Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *